Are you looking for a deep dive into the scientific and regulatory issues related to the demonstration of biosimilarity? How about the FDA’s current thinking on approaches to biosimilar development as well as perspectives of other regions? This bundle for $199 includes DIA 2012 sessions on these topics and much more.

Sessions included:
107 First-in-human Challenges of Biologics and Biosimilars
134 Regulatory Roundtable on Biosimilars
362 Emerging Development and Policy Trends in the Economics of the Biopharmaceutical Industry
384 Update on Biosimilar Developments in the US